Starpharma Holdings Past Earnings Performance
Past criteria checks 0/6
Starpharma Holdings has been growing earnings at an average annual rate of 6.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 12.6% per year.
Key information
6.5%
Earnings growth rate
8.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 12.6% |
Return on equity | -29.0% |
Net Margin | -83.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Starpharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 10 | -8 | 7 | 0 |
31 Mar 24 | 10 | -8 | 7 | 0 |
31 Dec 23 | 11 | -8 | 7 | 0 |
30 Sep 23 | 7 | -12 | 7 | 0 |
30 Jun 23 | 4 | -16 | 8 | 0 |
31 Mar 23 | 5 | -16 | 8 | 0 |
31 Dec 22 | 5 | -16 | 7 | 0 |
30 Sep 22 | 5 | -16 | 7 | 0 |
30 Jun 22 | 5 | -16 | 7 | 0 |
31 Mar 22 | 5 | -17 | 7 | 0 |
31 Dec 21 | 4 | -18 | 7 | 0 |
30 Sep 21 | 4 | -19 | 7 | 0 |
30 Jun 21 | 3 | -20 | 7 | 0 |
31 Mar 21 | 3 | -19 | 7 | 0 |
31 Dec 20 | 3 | -19 | 6 | 0 |
30 Sep 20 | 5 | -17 | 6 | 0 |
30 Jun 20 | 7 | -15 | 6 | 0 |
31 Mar 20 | 7 | -14 | 6 | 3 |
31 Dec 19 | 8 | -13 | 7 | 5 |
30 Sep 19 | 5 | -14 | 7 | 8 |
30 Jun 19 | 3 | -14 | 6 | 10 |
31 Mar 19 | 4 | -13 | 6 | 10 |
31 Dec 18 | 4 | -11 | 6 | 10 |
30 Sep 18 | 5 | -11 | 5 | 10 |
30 Jun 18 | 5 | -10 | 5 | 11 |
31 Mar 18 | 5 | -12 | 5 | 12 |
31 Dec 17 | 4 | -13 | 5 | 13 |
30 Sep 17 | 4 | -14 | 4 | 14 |
30 Jun 17 | 4 | -15 | 4 | 15 |
31 Dec 16 | 1 | -20 | 4 | 17 |
30 Sep 16 | 3 | -20 | 4 | 19 |
30 Jun 16 | 5 | -21 | 4 | 21 |
31 Mar 16 | 5 | -22 | 5 | 21 |
31 Dec 15 | 5 | -20 | 4 | 21 |
30 Sep 15 | 3 | -20 | 4 | 19 |
30 Jun 15 | 2 | -19 | 4 | 16 |
31 Mar 15 | 1 | -18 | 5 | 15 |
31 Dec 14 | 1 | -18 | 5 | 14 |
30 Sep 14 | 1 | -16 | 5 | 12 |
30 Jun 14 | 1 | -15 | 5 | 11 |
31 Mar 14 | 2 | -12 | 4 | 9 |
31 Dec 13 | 2 | -9 | 4 | 7 |
Quality Earnings: PQ6A is currently unprofitable.
Growing Profit Margin: PQ6A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PQ6A is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare PQ6A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PQ6A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).
Return on Equity
High ROE: PQ6A has a negative Return on Equity (-29.04%), as it is currently unprofitable.